CTRI/2020/07/026414已完成3 期
endTB: Evaluating Newly approved Drugs for multidrug-resistant TB
Medicins Sans Frontieres0 个研究点目标入组 31 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •A patient will be eligible for randomization if s/he:
- •1. Has documented pulmonary tuberculosis due to strains of M. tuberculosis resistant to rifampin (RIF) and susceptible to fluoroquinolones, diagnosed by validated rapid molecular test;
- •2. Is 15 years and more of age;
- •3. Is willing to use effective contraception: pre-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilized must agree to use two methods of contraception (e.g., a hormonal method and a barrier method) unless their partner has had a vasectomy; men who have not had a vasectomy must agree to use condoms;
- •4. Provides informed consent for study participation; additionally a legal representative of patients considered minor per local laws should also provide consent;
- •5. Lives in a dwelling that can be located by study staff and expects to remain in the area for the duration of the study.
排除标准
- •A patient will not be eligible for randomization if s/he:
- •1. Has known allergies or hypersensitivity to any of the investigational drugs;
- •2. Is known to be pregnant or is unwilling or unable to stop breast-feeding an infant;
- •3. Is unable to comply with treatment or follow-up schedule;
- •4. Has any condition (social or medical) which, in the opinion of the site principal investigator, would make study participant unsafe;
- •5. a. Has had exposure (intake of the drug for 30 days or more) in the past five years to bedaquiline, delamanid, linezolid, or clofazimine, or has proven or likely resistance to bedaquiline, delamanid, linezolid, or clofazimine (e.g., household contact of a DR-TB index case who died or experienced treatment failure after treatment containing bedaquiline, delamanid, linezolid, or clofazimine or had resistance to one of the listed drugs); exposure to other anti-TB drugs is not a reason for exclusion.b. Has received second-line drugs for 15 days or more prior to screening visit date in the current MDR/RR-TB treatment episode. Exceptions include: (1) patients whose treatment has failed according to the WHO definition151 and who are being considered for a new treatment regimen; (2) patients starting a new treatment regimen after having been lost to follow-up ? according to the WHO definition149 and, (3) patients in whom treatment failure is suspected (but not confirmed according to WHO definition), who are being considered for a new treatment regimen, and for whom the Clinical Advisory Committee (CAC) consultation establishes eligibility.
- •6. Has one or more of the following:
- •Hemoglobin treater than equal to 7.9 g/dL;
- •Uncorrectable electrolytes disorders:
- •Total Calcium < 7.0 mg/dL (1.75 mmol/L);
- •Potassium < 3.0 mEq/L (3.0 mmol/L) or more than or equal to 6.0 mEq/L (6.0 mmol/L);
- •Magnesium < 0.9 mEq/L (0.45 mmol/L);
- •Serum creatinine > 3 x ULN;
- •Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) more than/equal to 3 x ULN;
- •Total bilirubin 3 x ULN;
- •Albumin < 2.8 g/dL;
- •Unless otherwise specified, Grade 4 result as defined by the MSF Severity Scale (Appendix 2) on any of the screening laboratory tests.
- •7. Has cardiac risk factors defined as:
- •An arithmetic average of the two ECGs with highest QTcF intervals of greater than or equal to 450 ms. Retesting to reassess eligibility will be allowed using an unscheduled visit during the screening phase;
- •Evidence of ventricular pre-excitation (e.g., Wolff Parkinson White syndrome);
- •Electrocardiographic evidence of either:
- •Complete left bundle branch block or right bundle branch block; OR
- •Incomplete left bundle branch block or right bundle branch block and QRS complex duration > 120 msec on at least one ECG;
- •Having a pacemaker implant;
- •Congestive heart failure;
- •Evidence of second- or third-degree heart block;
- •Bradycardia as defined by sinus rate less than 50 bpm;
- •Personal or family history of Long QT Syndrome;
- •Personal history of arrhythmic cardiac disease, with the exception of sinus arrhythmia;
- •Personal history of syncope (i.e. cardiac syncope not including syncope due to vasovagal or epileptic causes).
- •8. Is currently taking part in another trial of a medicinal product;
- •9. Is taking any medication that is contraindicated with the medicines in the trial regi
研究者
相似试验
招募中
不适用
ENDTB - 2-A15 Respiratory tuberculosis, bacteriologically and histologically confirmedRespiratory tuberculosis, bacteriologically and histologically confirmedA15PER-038-16MEDICOS SIN FRONTERAS FRANCIA,287
进行中（未招募）
3 期
endTB-Q trials for Multidrug-Resistant TB with Fluoroquinolone Resistance.CTRI/2020/06/025618Medicins Sans Frontieres
招募中
不适用
EVALUATING NEWLY APPROVED DRUGS IN COMBINATION REGIMENS FOR MULTIDRUG-RESISTANT TB WITH FLUOROQUINOLONE RESISTANCE (Q)-A15 Respiratory tuberculosis, bacteriologically and histologically confirmedRespiratory tuberculosis, bacteriologically and histologically confirmedA15PER-020-20MEDICOS SIN FRONTERAS FRANCIA,
招募中
3 期
Evaluation of new drug treatments including artemisinin combination therapy for uncomplicated malaria in children in Papua New GuineaMalariaACTRN12605000550606niversity of Western Australia600
已完成
3 期
Clinical Evaluation of New Terumo drug elUting coRonary stent system in the treatment of patients with coronarY artery disease in Small Vessels in Japanese populatioIschemic heart diseaseJPRN-UMIN000012928Terumo Corporation70